Latest News & Features
Big Pharma
The EU General Court’s decision in September to fine Lundbeck nearly €150 million over several pay-for-delay deals will encourage the European Commission to take further action against similar agreements, say Bernd Allekotte and Franz Zimmer of Grünecker. 14 October 2016
Biotechnology
New legislation in Brazil aims to create a balance between using genetic resources for scientific advancement and spreading the benefits among local communities fairly, as Gabriel Di Blasi of Di Blasi, Parente & Associados and Eduardo Emrich of Biominas Brasil explain. 13 October 2016
Big Pharma
The UK government must ensure that the vital market for orphan drugs will continue to prosper following Brexit, says Kei Enomoto of Maucher Jenkins. 13 October 2016
Americas
Global companies are watching a pending life sciences patent case at the US Supreme Court because of its potential impact both within and outside US borders, as Sandra Kuzmich and Russell Garman of Frommer Lawrence & Haug explain. 12 October 2016
Africa
In a world where research projects are increasingly carried out by several parties in different countries, companies should consider a number of IP-related issues before embarking on multiterritorial collaborations, say Oliver Laing and Tony Proctor of Potter Clarkson. 12 October 2016
Asia
Over the past few years China’s life sciences sector has become a hive of activity as specialist IP courts have been implemented and M&A activity has ramped up. LSIPR assesses some of these developments. 11 October 2016
Big Pharma
In September 2016, the Francis Crick Institute opened the doors to its multimillion-pound new home in London. With a wide range of research being undertaken, LSIPR examines the role of IP and the associated challenges for the organisation. 11 October 2016
Biotechnology
Dolly the Sheep, which would have been 20 this year, raised the possibility of cloning and forced politicians and IP practitioners to address the ethics of the process, with differing results in the US and the UK, as LSIPR reports. 10 October 2016
Africa
There is some debate about whether the ‘patent cliff’ or the need to innovate is driving M&A activity in the pharmaceutical industry, where billions of dollars have been spent in the past few years, as LSIPR finds out. 10 October 2016
Americas
Roche is working hard to fight cancer and lead the way in personalised medicine, while at the same time dealing with patenting, litigation and other challenges, says chief IP counsel Mike Young in an interview with LSIPR. 7 October 2016